MENU
+Compare
ACAD
Stock ticker: NASDAQ
AS OF
Apr 11, 04:59 PM (EDT)
Price
$14.57
Change
+$0.46 (+3.26%)
Capitalization
2.43B

ACAD ACADIA Pharmaceuticals Forecast, Technical & Fundamental Analysis

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases... Show more

Industry: #Biotechnology
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ACAD with price predictions
Apr 10, 2025

ACAD's Indicator enters downward trend

The Aroon Indicator for ACAD entered a downward trend on April 10, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 255 similar instances where the Aroon Indicator formed such a pattern. In of the 255 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ACAD as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ACAD turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for ACAD crossed bearishly below the 50-day moving average on March 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ACAD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.319) is normal, around the industry mean (13.215). P/E Ratio (10.721) is within average values for comparable stocks, (62.474). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.735). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (2.532) is also within normal values, averaging (241.599).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACAD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ACAD is expected to report earnings to fall 102.49% to -2 cents per share on May 13

ACADIA Pharmaceuticals ACAD Stock Earnings Reports
Q1'25
Est.
$-0.02
Q4'24
Beat
by $0.64
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.05
The last earnings report on February 26 showed earnings per share of 86 cents, beating the estimate of 21 cents. With 1.90M shares outstanding, the current market capitalization sits at 2.43B.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals drugs for treatment of central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12830 El Camino Real
Phone
+1 858 558-2871
Employees
598
Web
https://www.acadia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME25.02-0.38
-1.50%
GameStop Corp
BTC.X79626.140000-2947.812500
-3.57%
Bitcoin cryptocurrency
AAPL190.42-8.43
-4.24%
Apple
SPY524.58-24.04
-4.38%
SPDR® S&P 500® ETF
TSLA252.40-19.80
-7.27%
Tesla

ACAD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-5.68%
RGNX - ACAD
49%
Loosely correlated
-8.46%
XNCR - ACAD
44%
Loosely correlated
-10.10%
HRTX - ACAD
43%
Loosely correlated
-3.19%
RCKT - ACAD
41%
Loosely correlated
-8.52%
DNLI - ACAD
41%
Loosely correlated
-2.80%
More